Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 5
2008 2
2009 1
2010 2
2011 4
2012 4
2013 6
2014 3
2015 5
2016 6
2017 4
2018 8
2019 9
2020 14
2021 14
2022 7
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
van de Haar J, Ma X, Ooft SN, van der Helm PW, Hoes LR, Mainardi S, Pinato DJ, Sun K, Salvatore L, Tortora G, Zurlo IV, Leo S, Giampieri R, Berardi R, Gelsomino F, Merz V, Mazzuca F, Antonuzzo L, Rosati G, Stavraka C, Ross P, Rodriquenz MG, Pavarana M, Messina C, Iveson T, Zoratto F, Thomas A, Fenocchio E, Ratti M, Depetris I, Cergnul M, Morelli C, Libertini M, Parisi A, De Tursi M, Zanaletti N, Garrone O, Graham J, Longarini R, Gobba SM, Petrillo A, Tamburini E, La Verde N, Petrelli F, Ricci V, Wessels LFA, Ghidini M, Cortellini A, Voest EE, Valeri N. van de Haar J, et al. Among authors: la verde n. Nat Med. 2023 Mar;29(3):605-614. doi: 10.1038/s41591-023-02240-8. Epub 2023 Mar 2. Nat Med. 2023. PMID: 36864254 Free PMC article. Clinical Trial.
Second medical opinion in oncological setting.
Maruzzo M, La Verde N, Russo A, Marchetti P, Scagnoli S, Gonzato O, Di Maio M, Zagonel V, Galvano A, Lanzetta G, Perrone F, Beretta G, Bordonaro R, Comandone A, Cinieri S, Nicolis F, Gori S. Maruzzo M, et al. Among authors: la verde n. Crit Rev Oncol Hematol. 2021 Apr;160:103282. doi: 10.1016/j.critrevonc.2021.103282. Epub 2021 Mar 3. Crit Rev Oncol Hematol. 2021. PMID: 33675905 Free article. Review.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Di Lisa FS, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, Borella F, Foglietta J, Cariello A, Ferro A, Picardo E, Mitidieri M, Sini V, Stani S, Tonini G, Santini D, La Verde N, Gambaro AR, Grassadonia A, Tinari N, Garrone O, Sarobba G, Livi L, Meattini I, D'Auria G, Vergati M, Gamucci T, Pistelli M, Berardi R, Risi E, Giotta F, Lorusso V, Rinaldi L, Artale S, Cazzaniga ME, Zustovich F, Cappuzzo F, Landi L, Torrisi R, Scagnoli S, Botticelli A, Michelotti A, Fratini B, Saltarelli R, Paris I, Muratore M, Cassano A, Gianni L, Gaspari V, Veltri EM, Zoratto F, Fiorio E, Fabbri MA, Mazzotta M, Ruggeri EM, Pedersini R, Valerio MR, Filomeno L, Minelli M, Scavina P, Raffaele M, Astone A, De Vita R, Pozzi M, Riccardi F, Greco F, Moscetti L, Giordano M, Maugeri-Saccà M, Zennaro A, Botti C, Pelle F, Cappelli S, Cavicchi F, Vizza E, Sanguineti G, Tomao F, Cortesi E, Marchetti P, Tomao S, Speranza I, Sperduti I, Ciliberto G, Vici P. Di Lisa FS, et al. Among authors: la verde n. Front Oncol. 2023 May 16;13:1152123. doi: 10.3389/fonc.2023.1152123. eCollection 2023. Front Oncol. 2023. PMID: 37260975 Free PMC article.
An overview of immune checkpoint inhibitors in breast cancer.
Miglietta F, Cona MS, Dieci MV, Guarneri V, La Verde N. Miglietta F, et al. Among authors: la verde n. Explor Target Antitumor Ther. 2020;1(6):452-472. doi: 10.37349/etat.2020.00029. Epub 2020 Dec 28. Explor Target Antitumor Ther. 2020. PMID: 36046385 Free PMC article. Review.
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. Among authors: la verde n. NPJ Breast Cancer. 2023 Sep 8;9(1):73. doi: 10.1038/s41523-023-00579-2. NPJ Breast Cancer. 2023. PMID: 37684252 Free PMC article.
COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
Silvestris N, Di Maio M, Russo A, Chiari R, De Giorgi U, Del Mastro L, Giuffrida D, La Verde N, Perrone F, Tucci M, Beretta GD, Cinieri S. Silvestris N, et al. Among authors: la verde n. ESMO Open. 2021 Apr;6(2):100100. doi: 10.1016/j.esmoop.2021.100100. Epub 2021 Mar 19. ESMO Open. 2021. PMID: 33819751 Free PMC article. Review.
Development and clinical indications of cetuximab.
Labianca R, La Verde N, Garassino MC. Labianca R, et al. Among authors: la verde n. Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S40-6. Int J Biol Markers. 2007. PMID: 17520580 Review.
Efficacy of biological agents in metastatic triple-negative breast cancer.
Bramati A, Girelli S, Torri V, Farina G, Galfrascoli E, Piva S, Moretti A, Dazzani MC, Sburlati P, La Verde NM. Bramati A, et al. Among authors: la verde nm. Cancer Treat Rev. 2014 Jun;40(5):605-13. doi: 10.1016/j.ctrv.2014.01.003. Epub 2014 Feb 4. Cancer Treat Rev. 2014. PMID: 24529896 Review.
89 results